Satu Mäkelä

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Estrogen-Specific 17 -Hydroxysteroid Oxidoreductase Type 1 (E.C. 1.1.1.62) as a Possible Target for the Action of Phytoestrogens

Satu Mäkelä, Matti Poutanen, Jaakko Lehtimäki et al. · Experimental Biology and Medicine · 1995 · 166 citations

Life Sciences, Cancer Biology, Medicinal Chemistry +17

Inhibition of 17 -Hydroxysteroid Oxidoreductase by Flavonoids in Breast and Prostate Cancer Cells

Satu Mäkelä, Matti Poutanen, M. L. Kostian et al. · Experimental Biology and Medicine · 1998 · 139 citations

Life Sciences, Biochemistry, Pharmacology +16

Detection of human norovirus from frozen raspberries in a cluster of gastroenteritis outbreaks

Leena Maunula, Merja Roivainen, M Keränen et al. · Eurosurveillance · 2009 · 118 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Human Leukocyte Antigen–B8‐DR3 Is a More Important Risk Factor for Severe Puumala Hantavirus Infection than the Tumor Necrosis Factor–α(−308) G/A Polymorphism

Satu Mäkelä, Jukka Mustonen, Ilpo Ala‐Houhala et al. · The Journal of Infectious Diseases · 2002 · 110 citations

Life Sciences, Genetics, Immunology +17